ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

Phase 1

Recruiting

Conditions: Hematologic Malignancies

Interventions: Drug: Venetoclax
Drug: ethinyl estradiol/levonorgestrel

First Posted Date: 2018-06-15

Last Posted Date: 2024-08-29

Lead Sponsor: AbbVie

Target Recruit Count: 12

Registration Number: NCT03557619

Locations: 🇺🇸
Duplicate_Henry Ford Health System /ID# 209090, Detroit, Michigan, United States
🇦🇺
Peter MacCallum Cancer Centre-East Melbourne /ID# 225247, East Melbourne, Victoria, Australia
🇺🇸
Gabrail Cancer Center Research /ID# 207039, Canton, Ohio, United States

and more 1 locations

A Long-Term Study of Rovalpituzumab Tesirine

Phase 2

Completed

Conditions: Cancer

Interventions: Drug: rovalpituzumab tesirine

First Posted Date: 2018-06-01

Last Posted Date: 2021-01-05

Lead Sponsor: AbbVie

Target Recruit Count: 3

Registration Number: NCT03543358

Locations: 🇺🇸
Arizona Oncology Associates, PC-HOPE (Rudasill) /ID# 204818, Tucson, Arizona, United States
🇺🇸
City of Hope National Medical Center /ID# 204885, Duarte, California, United States
🇺🇸
Univ of Pittsburgh Med Ctr /ID# 204763, Pittsburgh, Pennsylvania, United States

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: Pomalidomide
Drug: Venetoclax

First Posted Date: 2018-05-29

Last Posted Date: 2024-07-19

Lead Sponsor: AbbVie

Target Recruit Count: 265

Registration Number: NCT03539744

Locations: 🇺🇸
University of Maryland Medical Center /ID# 217422, Baltimore, Maryland, United States
🇺🇸
UPMC Hillman Cancer Ctr /ID# 200063, Pittsburgh, Pennsylvania, United States
🇺🇸
Cleveland Clinic Main Campus /ID# 202247, Cleveland, Ohio, United States

and more 177 locations

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Telisotuzumab vedotin

First Posted Date: 2018-05-29

Last Posted Date: 2024-01-19

Lead Sponsor: AbbVie

Target Recruit Count: 270

Registration Number: NCT03539536

Locations: 🇺🇸
Veterans Healthcare System /ID# 215602, Pittsburgh, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital /ID# 203215, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center /ID# 208124, Boston, Massachusetts, United States

and more 249 locations

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

Phase 4

Completed

Conditions: Hypogonadism
Cardiovascular Diseases

Interventions: Drug: AndroGel®
Drug: Placebo

First Posted Date: 2018-05-08

Last Posted Date: 2024-03-13

Lead Sponsor: AbbVie

Target Recruit Count: 5246

Registration Number: NCT03518034

Locations: 🇺🇸
Founders Research Corp /ID# 170610, Philadelphia, Pennsylvania, United States
🇺🇸
Alliance for Multispecialty Research- Norman /ID# 170581, Norman, Oklahoma, United States
🇺🇸
Maryland Cardiovascular Specialists /ID# 168057, Baltimore, Maryland, United States

and more 381 locations

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: risankizumab
Drug: placebo for rizankizumab

First Posted Date: 2018-05-08

Last Posted Date: 2021-01-25

Lead Sponsor: AbbVie

Target Recruit Count: 50

Registration Number: NCT03518047

Locations: 🇷🇺
GBUZ Clinical Dermatovenerology Dispensary of MoH of Krasnodar region /ID# 201713, Krasnodar, Krasnodarskiy Kray, Russian Federation
🇷🇺
LLC Kurator /ID# 200616, Saint-Petersburg, Sankt-Peterburg, Russian Federation
🇷🇺
Alliance Biomedical Ural Group /ID# 201681, Izhevsk, Udmurtskaya Respublika, Russian Federation

and more 3 locations

A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)

Completed

Conditions: Ankylosing Spondylitis (AS)

First Posted Date: 2018-04-23

Last Posted Date: 2023-07-20

Lead Sponsor: AbbVie

Target Recruit Count: 28

Registration Number: NCT03505892

Locations: 🇨🇳
Hualien Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation, Hualien City, Taiwan

Expanded Access to Rovalpituzumab Tesirine

Conditions: Small Cell Lung Cancer

First Posted Date: 2018-04-20

Last Posted Date: 2019-09-10

Lead Sponsor: AbbVie

Registration Number: NCT03503890

A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Cancer - Acute Myeloid Leukemia

Interventions: Drug: Venetoclax
Drug: Dinaciclib

First Posted Date: 2018-03-30

Last Posted Date: 2022-12-30

Lead Sponsor: AbbVie

Target Recruit Count: 48

Registration Number: NCT03484520

Locations: 🇺🇸
David Geffen School of Medicin /ID# 200015, Los Angeles, California, United States
🇺🇸
The Ohio State University /ID# 200668, Columbus, Ohio, United States
🇦🇺
Gold coast University Hospital /ID# 202759, SouthPort, Queensland, Australia

and more 10 locations

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: secukinumab
Drug: risankizumab

First Posted Date: 2018-03-27

Last Posted Date: 2021-07-13

Lead Sponsor: AbbVie

Target Recruit Count: 327

Registration Number: NCT03478787

Locations: 🇨🇦
Beacon Dermatology Inc /ID# 203054, Calgary, Alberta, Canada
🇫🇷
Hopital Saint-Louis /ID# 203586, Paris, France
🇺🇸
Progressive Medical Research /ID# 202183, Port Orange, Florida, United States

and more 58 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy